磁共振波谱在乳腺癌诊断与治疗中的应用
MR Spectroscopy in the diagnosis and treatment of breast cancer.
作者信息
Nelson Michael T, Everson Lenore I, Garwood Michael, Emory Tim, Bolan Patrick J
机构信息
University of Minnesota Medical School, Department of Radiology, Center for Magnetic Resonance Imaging, Minneapolis, MN 55455.
出版信息
Semin Breast Dis. 2008 Jun 1;11(2):100-105. doi: 10.1053/j.sembd.2008.03.004.
Abstract
In vivo proton magnetic resonance spectroscopy ((1)H MRS) is rapidly becoming useful as a clinical tool for diagnosing and characterizing breast cancers. Alterations of the levels of choline-containing metabolites are associated with malignancy. High-field MR scanners at 1.5 T, 3 T, 4 T, and 7 T have been used to evaluate the role of (1)H MRS measurements of total choline containing compounds in patients with breast cancer. This article will review clinical use of MRI/MRS in vivo. Newer developments in high field MR scanning and quantitative MRS may help breast imagers improve sensitivity and specificity in diagnosing and treating breast cancer.
摘要
体内质子磁共振波谱（(1)H MRS）正迅速成为一种用于诊断和表征乳腺癌的临床工具。含胆碱代谢物水平的改变与恶性肿瘤相关。1.5T、3T、4T和7T的高场磁共振扫描仪已被用于评估(1)H MRS测量乳腺癌患者中总含胆碱化合物的作用。本文将综述MRI/MRS在体内的临床应用。高场磁共振扫描和定量MRS的最新进展可能有助于乳腺成像人员提高诊断和治疗乳腺癌的敏感性和特异性。
相似文献
1
MR Spectroscopy in the diagnosis and treatment of breast cancer.
Semin Breast Dis. 2008 Jun 1;11(2):100-105. doi: 10.1053/j.sembd.2008.03.004.
2
Metabolite quantification and high-field MRS in breast cancer.
NMR Biomed. 2009 Jan;22(1):65-76. doi: 10.1002/nbm.1217.
3
The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy.
Breast Cancer Res Treat. 2001 Jul;68(1):45-54. doi: 10.1023/a:1017911211090.
4
In vivo MR spectroscopy for breast cancer diagnosis.
BJR Open. 2019 Jul 2;1(1):20180040. doi: 10.1259/bjro.20180040. eCollection 2019.
5
Application value of 3T ¹H-magnetic resonance spectroscopy in diagnosing breast tumors.
Acta Radiol. 2013 May;54(4):380-8. doi: 10.1177/0284185113475921. Epub 2013 Apr 30.
6
MRI and (1)H MRS of the breast: presence of a choline peak as malignancy marker is related to K21 value of the tumor in patients with invasive ductal carcinoma.
Breast J. 2008 Nov-Dec;14(6):574-80. doi: 10.1111/j.1524-4741.2008.00650.x. Epub 2008 Oct 13.
7
Is Elevated Choline on Magnetic Resonance Spectroscopy a Reliable Marker of Breast Lesion Malignancy?
Front Oncol. 2021 Sep 10;11:610354. doi: 10.3389/fonc.2021.610354. eCollection 2021.
8
[Influences of Tumor Volume and FWHM of the Water Peak and T* Value of Water on the Detection Rate of the Choline Peaks in Proton MR Spectroscopy of Breast Cancer at 3.0 T-MRI].
Nihon Hoshasen Gijutsu Gakkai Zasshi. 2021;77(4):351-357. doi: 10.6009/jjrt.2021_JSRT_77.4.351.
9
Ex vivo proton MR spectroscopy (1H-MRS) for evaluation of human gastric carcinoma.
Magn Reson Imaging. 2004 Jul;22(6):861-70. doi: 10.1016/j.mri.2004.01.045.
10
In vivo proton magnetic resonance spectroscopy of breast lesions: an update.
Breast Cancer Res Treat. 2007 Sep;104(3):249-55. doi: 10.1007/s10549-006-9412-8. Epub 2006 Oct 19.
引用本文的文献
1
Automated Acquisition Planning for Magnetic Resonance Spectroscopy in Brain Cancer.
Med Image Comput Comput Assist Interv. 2020 Oct;12267:730-739. doi: 10.1007/978-3-030-59728-3_71. Epub 2020 Sep 29.
2
Magnetic Resonance Spectroscopy Studies of Mouse Models of Cancer.
Methods Mol Biol. 2018;1718:331-345. doi: 10.1007/978-1-4939-7531-0_20.
3
CEST-MRI detects metabolite levels altered by breast cancer cell aggressiveness and chemotherapy response.
NMR Biomed. 2016 Jun;29(6):806-16. doi: 10.1002/nbm.3526. Epub 2016 Apr 21.
4
Differential diagnosis between malignant and benign breast lesions using single-voxel proton MRS: a meta-analysis.
J Cancer Res Clin Oncol. 2014 Jun;140(6):993-1001. doi: 10.1007/s00432-014-1605-7. Epub 2014 Mar 6.
本文引用的文献
1
Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI.
Technol Cancer Res Treat. 2006 Aug;5(4):401-10.
2
Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T.
MAGMA. 2006 May;19(2):96-104. doi: 10.1007/s10334-006-0032-4. Epub 2006 May 9.
3
Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.
Radiology. 2006 Jun;239(3):686-92. doi: 10.1148/radiol.2393051046. Epub 2006 Apr 7.
4
Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T.
Radiology. 2005 Aug;236(2):465-75. doi: 10.1148/radiol.2362040836.
5
An improved 1H magnetic resonance spectroscopic imaging technique for the human breast: preliminary results.
Magn Reson Imaging. 2005 May;23(4):571-6. doi: 10.1016/j.mri.2005.02.011.
6
Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T.
Radiology. 2004 Nov;233(2):424-31. doi: 10.1148/radiol.2332031285.
7
Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T.
Eur Radiol. 2005 May;15(5):1037-43. doi: 10.1007/s00330-004-2475-1. Epub 2004 Sep 3.
8
Detection of breast malignancy: diagnostic MR protocol for improved specificity.
Radiology. 2004 Aug;232(2):585-91. doi: 10.1148/radiol.2322030547. Epub 2004 Jun 17.
9
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.
Cancer Res. 2004 Jun 15;64(12):4270-6. doi: 10.1158/0008-5472.CAN-03-3829.
10
From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design.
Cancer Lett. 2004 Apr 8;206(2):137-48. doi: 10.1016/j.canlet.2003.08.031.
Zotero 插件